Aysenur Elmali¹, Birhan Demirhan², Caglayan Selenge Beduk Esen³, Ozan Cem Guler⁴, Pervin Hurmuz⁵, Cem Onal^1,4,*

Canadian Journal of Urology, Vol.32, No.4, pp. 243-254, 2025, DOI:10.32604/cju.2025.066700 - 29 August 2025

Abstract Background: Intermediate-risk prostate cancer (IR-PC) represents a heterogeneous group requiring nuanced treatment approaches, and recent advancements in radiotherapy (RT), androgen deprivation therapy (ADT), and prostate-specific membrane antigen positron emission tomography (PSMA-PET/CT) imaging have prompted growing interest in personalized, risk-adapted management strategies. This study by the Turkish Society for Radiation Oncology aims to examine radiation oncologists’ practices in managing IR-PC, focusing on RT and imaging modalities to identify trends for personalized treatments. Methods: A cross-sectional survey was conducted among Turkish radiation oncologists treating at least 50 prostate cancer (PC) cases annually. The 22-item questionnaire covered IR-PC… More >

LOKMAN VARISLI^1,2, VEYSEL TOLAN¹, JIYAN H. CEN³, SPIROS VLAHOPOULOS⁴, OSMAN CEN^5,6,*

Oncology Research, Vol.30, No.3, pp. 137-155, 2022, DOI:10.32604/or.2022.026074 - 12 January 2023

Abstract Prostate cancer is one of the most often diagnosed malignancies in males and its prevalence is rising in both developed and developing countries. Androgen deprivation therapy has been used as a standard treatment approach for advanced prostate cancer for more than 80 years. The primary aim of androgen deprivation therapy is to decrease circulatory androgen and block androgen signaling. Although a partly remediation is accomplished at the beginning of treatment, some cell populations become refractory to androgen deprivation therapy and continue to metastasize. Recent evidences suggest that androgen deprivation therapy may cause cadherin switching, from More >

Margaret E. Long¹, Andrew M. Vitale², Sarah L. Mott³, Chad Tracy², Rohan Garje³, Yousef Zakharia³, James A. Brown²

Canadian Journal of Urology, Vol.28, No.4, pp. 10738-10742, 2021

Abstract Introduction: Androgen deprivation therapy (ADT) is often used in the treatment of prostate cancer. Specific factors affecting testosterone recovery after cessation of ADT have not been well-characterized in existing literature.
Materials and methods: We retrospectively reviewed patients at our institution who received ADT between 1999 and 2018. Patients with at least one course of ADT and subsequent testosterone level within 12 months of cessation of ADT were included. Patients received at least one of the following four agents: leuprolide, goserelin, triptorelin, and degarelix. Cox regression models were utilized to estimate the effect of patient and treatment characteristics… More >

Richard J. Wassersug, John Robinson, R. Psych, Lauren Walker

Canadian Journal of Urology, Vol.25, No.6, pp. 9568-9568, 2018

Abstract This article has no abstract. More >

Yanqun Dong¹, Karen J. Ruth², Thomas M. Churilla¹, Rosalia Viterbo³, Mark L. Sobczak¹, Marc C. Smaldone³, David Y.T. Chen³, Robert G. Uzzo³, Mark H. Hallman¹, Eric M. Horwitz¹

Canadian Journal of Urology, Vol.24, No.1, pp. 8656-8662, 2017

Abstract Introduction: To evaluate if androgen deprivation therapy (ADT) improves outcomes for patients with localized, intermediate-risk prostate cancer treated with definitive external beam radiation therapy (EBRT) in the dose-escalated era.
Materials and methods: This is a retrospective study using a single institutional database. We included patients with localized, intermediate-risk prostate cancer treated with dose-escalated radiation therapy (RT) with 3D conformal radiotherapy or intensity-modulated radiotherapy (74-80 Gy in daily fraction of 1.8 Gy-2.0 Gy, or 70.2 Gy in daily fraction of 2.7 Gy) from 1992 to 2013. To further risk stratify the patients, PSA 10 ng/mL-20 ng/mL, Gleason 3+4,… More >

Rutveej Patel¹, Izak Faiena¹, Jules Geltzeiler²

Canadian Journal of Urology, Vol.22, No.2, pp. 7752-7754, 2015

Abstract We present a case of a 75-year-old male with a history of high risk prostate cancer who underwent androgen deprivation therapy and palliative radiation treatments for his disease. Subsequently, he presented with gross hematuria and severe lower urinary tract symptoms. A palliative transurethral resection of the prostate (TURP) at that time, demonstrated large cell differentiated neuroendocrine carcinoma with metastasis to the lung. We review the limited literature on this rare form of disease and present current treatment strategies. More >

Lior M. Hirsch, Larry E. Goldstein

Canadian Journal of Urology, Vol.22, No.4, pp. 7938-7941, 2015

Abstract In men with advanced carcinoma of the prostate being treated with androgen deprivation therapy (ADT), hot flashes can be a significant side effect of the treatment. In this paper we describe using acupuncture as a complementary alternative therapy for treatment of hot flashes in men. More >

Valentina Butoescu, Bertrand Tombal

Canadian Journal of Urology, Vol.21, Suppl.2, pp. 84-92, 2014

Abstract instruction: Introduction: In the advanced stage of prostate cancer, bone is consistently the first and, later on, the dominant extra-nodal metastatic site. Bone metastases account for most of prostate cancer's morbidity.
instruction: Materials and methods: We have performed a literature review using the MEDLINE database for publications on: 1) bone metastases (androgen deprivation therapy); 2) cancer treatment-induced bone loss; 3) skeletal-related events; 4) denosumab; 5) zoledronic acid.
instruction: Results: Prostate cancer cells disrupt the normal bone remodeling process, invade the skeletal environment, and ultimately weaken the bone structure. This may result in skeletal complications, also known as skeletal-related… More >

Shawn Dason, Christopher Brian Allard, Jing Gennie Wang, Jen Hoogenes, Bobby Shayegan

Canadian Journal of Urology, Vol.21, Suppl.2, pp. 28-36, 2014

Abstract instruction: Introduction: Intermittent androgen deprivation therapy (IADT) for prostate cancer involves cycles of androgen deprivation therapy (ADT) with a period between cycles where testosterone is allowed to rise above castrate levels. A number of recent randomized controlled trials (RCTs) have compared survival and health-related quality-of-life (HRQOL) between IADT and continuous ADT (CADT). This review seeks to critically analyze these published trials for their relevance to clinical practice.
instruction: Materials and methods: Published trials were retrieved from a systematic search of MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials databases using relevant keywords. Recent systematic reviews… More >

Kyle O. Rove, E. David Crawford

Canadian Journal of Urology, Vol.21, Suppl.2, pp. 14-21, 2014

Abstract instruction: Introduction: Androgen deprivation therapy (ADT) is a mature therapy for the treatment of advanced prostate cancer, and yet despite many years of use, there is still much about its use, side effects, efficacy, and outcomes for which the urology community does not have answers.
instruction: Materials and methods: A literature search was performed to review ADT use in the modern era, specifically examining adjuvant ADT after primary therapy, continuous versus intermittent ADT, disadvantages of luteinizing hormone-releasing hormone (LHRH) agonists versus newer LHRH antagonists, and controversies of combined androgen blockade.
instruction: Results: ADT has little role as primary… More >